Generic NuvaRing Availability

NuvaRing is a brand name of ethinyl estradiol/etonogestrel, approved by the FDA in the following formulation(s):

NUVARING (ethinyl estradiol; etonogestrel - ring;vaginal)

  • Manufacturer: ORGANON USA INC
    Approval date: October 3, 2001
    Strength(s): 0.015MG/24HR;0.12MG/24HR [RLD]

Has a generic version of NuvaRing been approved?

No. There is currently no therapeutically equivalent version of NuvaRing available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of NuvaRing. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Drug delivery system for two or more active substances
    Patent 5,989,581
    Issued: November 23, 1999
    Inventor(s): Groenewegen; Rudolf Johannes Joseph
    Assignee(s): Akzo Nobel N.V.
    The present invention is dealing with a drug delivery system, preferably in a ring-shaped form suitable for vaginal administration, for the simultaneous release of a progestogenic steroid compound and an estrogenic steroid compound in a fixed physiological ratio over a prolonged period of time. The drug delivery system comprises at least one compartment comprising a thermoplastic polymer core containing the mixture of the progestogenic and estrogenic compounds and a thermoplastic polymer skin, the progestogenic compound being initially dissolved in the polymer core material in a relatively low degree of supersaturation.
    Patent expiration dates:
    • April 8, 2018

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web2)